TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31196132

Group type: EXPERIMENTAL
Intervention: Standard treatment plus clindamycin for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment (flucloxacillin/cefazolin for MSSA; vancomycin/daptomycin for MRSA)
Number of subjects: 60
Study: 28327804

Group type: COMPARATOR
Intervention: N-methylglucamine antimoniate (20mg/kg/day for 20 days)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate (1 mg/kg/day for 14 days)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups (N-methylglucamine antimoniate and amphotericin B)
Number of subjects: 101
Study: 25232714

Group type: EXPERIMENTAL
Intervention: Perioperative enteral immunonutrition (EIN)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard enteral nutrition (SEN)
Number of subjects: 37
Study: 23836966

Group type: EXPERIMENTAL
Intervention: Patient education on falls prevention in hospital
Number of subjects: 138
Study: 21074752

Group type: EXPERIMENTAL
Intervention: ACT intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 93
Study: 19179026

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogen 0.625mg/day
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Intranasal 300microg/day estradiol hemihidrate
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Percutaneous gel 1.5mg/day estradiol hemihidrate
Number of subjects: 132

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 132
Study: 17370331

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Variceal banding
Number of subjects: 62
Study: 15382785

Group type: EXPERIMENTAL
Intervention: Lithia disilicate-based core ceramic for posterior FPDs
Number of subjects: 30
Study: 11440787

Group type: EXPERIMENTAL
Intervention: Bretschenider solution (HTK)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional crystalloid cardioplegia
Number of subjects: 30
Study: 9593395

Group type: EXPERIMENTAL
Intervention: 0.02% MMC for 5 minutes
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.04% MMC for 5 minutes
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.02% MMC for 3 minutes
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.04% MMC for 3 minutes
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control with no MMC
Number of subjects: 180
Study: 7972649

Group type: EXPERIMENTAL
Intervention: Relaxation therapy with respiratory feedback (RFB)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 170
Study: 2656335

Group type: EXPERIMENTAL
Intervention: 10 mg famotidine twice daily
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine at bedtime
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 209
Study: 30265016

Group type: EXPERIMENTAL
Intervention: VSST: Veteran‐Supportive Supervisor Training
Number of subjects: 497

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 497
Study: 28600210

Group type: EXPERIMENTAL
Intervention: Accelerated epirubicin (100 mg/m2 every 2 weeks with 6 mg pegfilgrastim on day 2)
Number of subjects: 4391

Group type: COMPARATOR
Intervention: Standard epirubicin (100 mg/m2 every 3 weeks)
Number of subjects: 4391

Group type: EXPERIMENTAL
Intervention: Capecitabine (2500 mg/m2, 1250 mg/m2 given twice daily on days 1-14 of each cycle)
Number of subjects: 4391

Group type: COMPARATOR
Intervention: CMF (600 mg/m2 cyclophosphamide, 40 mg/m2 methotrexate, 600 mg/m2 fluorouracil)
Number of subjects: 4391

Group type: COMPARATOR
Intervention: Standard epirubicin
Number of subjects: 4391

Group type: EXPERIMENTAL
Intervention: Accelerated epirubicin
Number of subjects: 4391

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 4391

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 4391
Study: 25499587

Group type: EXPERIMENTAL
Intervention: Immediate insertion of Copper T380A IUD
Number of subjects: 68

Group type: COMPARATOR
Intervention: Delayed insertion of Copper T380A IUD (6 weeks post-cesarean)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IUD users (both groups)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nonusers (both groups)
Number of subjects: 68
Study: 24024040

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21315637

Group type: EXPERIMENTAL
Intervention: PedsQL 4.0 Generic Core Scales (self-reported)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: PedsQL 4.0 Generic Core Scales (parent proxy-reported)
Number of subjects: 179

Group type: COMPARATOR
Intervention: PedsQL scores in pediatric patients with ADHD and comorbid psychiatric disorders
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: ADHD symptom severity
Number of subjects: 179
Study: 19625119

Group type: EXPERIMENTAL
Intervention: Bleaching with supplementary light exposure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bleaching without supplementary light exposure
Number of subjects: 20
Study: 17893502

Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 872

Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 872
Study: 15473195

Group type: EXPERIMENTAL
Intervention: 2-D linear method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-D nonlinear method
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1-D linear method
Number of subjects: 0
Study: 11483171

Group type: EXPERIMENTAL
Intervention: New Zealand pre-readers (English, Roman alphabet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guangzhou reading children (alphabetic Pinyin and logographic Chinese)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hong Kong pre-readers (logographic Chinese)
Number of subjects: 0
Study: 9786563

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg, two capsules)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (two identical appearing capsules)
Number of subjects: 26
Study: 8156351

Group type: EXPERIMENTAL
Intervention: Levovist 300 mg/ml (10 ml intravenous injection)
Number of subjects: 26
Study: 2845188

Group type: EXPERIMENTAL
Intervention: Sodium valproate (single dose and long term administration)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 12
Study: 30919899

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg daily
Number of subjects: 30937

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg daily
Number of subjects: 30937

Group type: EXPERIMENTAL
Intervention: Combination of ramipril and telmisartan
Number of subjects: 30937

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 30937
Study: 27085768

Group type: EXPERIMENTAL
Intervention: Social cognitive theory‐based weight‐management treatments emphasizing physical activity‐derived self‐regulation (n=53)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Review of a written manual and phone support (n=54)
Number of subjects: 107
Study: 25521188

Group type: EXPERIMENTAL
Intervention: 20 g SQ-LNS with varying contents of zinc
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: Dispersible tablet containing 0 or 5 mg zinc
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: SQ-LNS
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: Dispersible tablet
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: Plasma zinc concentration
Number of subjects: 2435
Study: 23764385

Group type: EXPERIMENTAL
Intervention: Lithium treatment (mean blood level 0.67 mEq/L)
Number of subjects: 24
Study: 21343159

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 2% (1.5 mg kg(‐1) bolus at induction followed by 2.0 mg kg(‐1) h(‐1) infusion)
Number of subjects: 99
Study: 17609296

Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg every 2 weeks by intramuscular injection with placebo pill daily)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Testosterone plus Finasteride (200 mg of T every 2 weeks by intramuscular injection with 5 mg of finasteride daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (placebo injections and pills)
Number of subjects: 69
Study: 15728645

Group type: EXPERIMENTAL
Intervention: Acute insulin-glucose infusion followed by insulin-based long-term glucose control (Group 1)
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Insulin-glucose infusion followed by standard glucose control (Group 2)
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Routine metabolic management according to local practice (Group 3)
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: All groups (1-3 combined)
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: All groups (1-3)
Number of subjects: 1253
Study: 12480479

Group type: EXPERIMENTAL
Intervention: Home-made 'language' using gestures in communicative contexts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-communicative context using pictures for reconstruction
Number of subjects: 0
Study: 9790158

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8547097

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIII (r-VIII SQ, Pharmacia, Sweden)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 2696506

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plus fentanyl 75 mcg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 14
Study: 1104246

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate solution, twice a day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine solution
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 54
Study: 30195275

Group type: EXPERIMENTAL
Intervention: Balloon catheter sinuplasty (BCS) added to adenoidectomy with maxillary sinus irrigation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Adenoidectomy with maxillary sinus irrigation alone (Control)
Number of subjects: 25
Study: 27595811

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention to reduce risky alcohol use during hospitalization
Number of subjects: 141
Study: 23850885

Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscopy (GVL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscopy with bougie (GVL-B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of GVL to DL
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of GVL-B to DL
Number of subjects: 20
Study: 21838784

Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: itraconazole 100 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: gemfibrozil-itraconazole combination
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 20578781

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus oral antidiabetes drugs (OADs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Premixed insulin only
Number of subjects: 0
Study: 18395908

Group type: EXPERIMENTAL
Intervention: Prometheus liver assist system (n = 8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Molecular Adsorbent Recirculation System (MARS) (Control group 1, n = 8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hemodialysis (Control group 2, n = 8)
Number of subjects: 24
Study: 16087029

Group type: EXPERIMENTAL
Intervention: Dexamethasone inner ear perfusion (4 mg/mL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 22
Study: 12600856

Group type: EXPERIMENTAL
Intervention: Iron supplementation (10 mg Fe, 5 d/wk for 6 mo)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg Zn, 5 d/wk for 6 mo)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (2.4 mg beta-carotene, 5 d/wk for 6 mo)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Iron + Zinc supplementation (10 mg each, 5 d/wk for 6 mo)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study: 11214351

Group type: EXPERIMENTAL
Intervention: Vitamin A, 3 mg retinol equivalent/day
Number of subjects: 697

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 697
Study: 8626351

Group type: EXPERIMENTAL
Intervention: Valproate (given twice daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lithium (added on Days 6-10)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (given twice daily)
Number of subjects: 16
Study: 1601510

Group type: EXPERIMENTAL
Intervention: Polyamide (PAM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile (AN69)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both membranes
Number of subjects: 10
Study: 6429875

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional Oral Nutritional Support (CN)
Number of subjects: 32
Study: 30832638

Group type: EXPERIMENTAL
Intervention: 6 month text message intervention (DTEXT)
Number of subjects: 340
Study: 29290208

Group type: EXPERIMENTAL
Intervention: Postmenopausal women aged 50-54.9 years
Number of subjects: 932

Group type: COMPARATOR
Intervention: Women aged 60-64.9 years
Number of subjects: 932

Group type: COMPARATOR
Intervention: Women aged ≥65 years
Number of subjects: 932
Study: 26935065

Group type: EXPERIMENTAL
Intervention: albendazole-oxantel pamoate
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: albendazole-ivermectin
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: albendazole
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: mebendazole
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 405
Study: 24456057

Group type: EXPERIMENTAL
Intervention: Virtual reality-based balance intervention using a Nintendo Wii
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard physical therapy modalities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Virtual reality and Standard physical therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wii balance board game scores
Number of subjects: 0
Study: 22689471

Group type: EXPERIMENTAL
Intervention: 400 mL FV-puree-based drink (FVPD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no FVPD)
Number of subjects: 24
Study: 20009917

Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine
Number of subjects: 80
Study: 17602081

Group type: EXPERIMENTAL
Intervention: Gemcitabine-docetaxel
Number of subjects: 122

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 122
Study: 16123718

Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 90
Study: 11887168

Group type: EXPERIMENTAL
Intervention: Premenopausal women
Number of subjects: 69

Group type: COMPARATOR
Intervention: Postmenopausal women
Number of subjects: 69
Study: 10609985

Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 15 mg/5 mL
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 30 mg/5 mL
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study: 8538895

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.5 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rectal midazolam 0.5 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both routes
Number of subjects: 60
Study: 1650015

Group type: EXPERIMENTAL
Intervention: GM-CSF 50 micrograms/m2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: GM-CSF 500 micrograms/m2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: GM-CSF during chemotherapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Chemotherapy without GM-CSF
Number of subjects: 17
Study: 6345596

Group type: EXPERIMENTAL
Intervention: Triple regimen (chlorthalidone 25 mg/day, oxdralazine 20 mg/day, propranolol 40 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Double regimen (chlorthalidone 25 mg/day, propranolol 103 mg/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Triple regimen (chlorthalidone 25 mg/day, oxdralazine 56 mg/day, propranolol 112 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Double regimen (chlorthalidone 25 mg/day, propranolol 222 mg/day)
Number of subjects: 29
Study: 31434737

Group type: EXPERIMENTAL
Intervention: DNA/rAd5 HIV vaccine regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29800637

Group type: EXPERIMENTAL
Intervention: Sealing caries with a flowable resin (SC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Partial removal of caries followed by restoration (PRC)
Number of subjects: 28
Study: 26258462

Group type: EXPERIMENTAL
Intervention: Educational workshops on diet (4-5 sessions)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (no workshops)
Number of subjects: 148
Study: 23203821

Group type: EXPERIMENTAL
Intervention: IFN‐K (30 μg, 60 μg, 120 μg, or 240 μg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: IFN‐K
Number of subjects: 28
Study: 21356025

Group type: EXPERIMENTAL
Intervention: 0.05% cetyl-pyridinium chloride mouth rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine and CPC (positive control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control (similar to the test product, without active ingredients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gingival index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total colony forming units
Number of subjects: 0
Study: 19506491

Group type: EXPERIMENTAL
Intervention: Jobskin pressure garments and Mepiform silicone sheeting
Number of subjects: 22

Group type: COMPARATOR
Intervention: Jobskin pressure garments alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pressure therapy (PT) group
Number of subjects: 22
Study: 16790659

Group type: EXPERIMENTAL
Intervention: 30 mg of 1% preservative free 2‐chloroprocaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 40 mg of 1% preservative free 2‐chloroprocaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 50 mg of 1% preservative free 2‐chloroprocaine
Number of subjects: 45
Study: 12734530

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 196
Study: 11051136

Group type: EXPERIMENTAL
Intervention: Ciclopirox nail lacquer 8%
Number of subjects: 460
Study: 9077496

Group type: EXPERIMENTAL
Intervention: Diffuse Lewy body disease (DLBD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alzheimer-type dementia (ATD)
Number of subjects: 0
Study: 8418720

Group type: EXPERIMENTAL
Intervention: Caudal nerve block with 0.25% bupivacaine, 0.75 mL/kg (group I)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Caudal nerve block with 0.25% bupivacaine and 1:200,000 epinephrine, 0.75 mL/kg (group II)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ilioinguinaliliohypogastric nerve block with epinephrine (group III)
Number of subjects: 82
Study: 3511376

Group type: EXPERIMENTAL
Intervention: Antacid treatment (suspension, 400 mg, one and three hours after meals)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg, twice a day)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 29796595

Group type: EXPERIMENTAL
Intervention: Crushed and suspended TRI with fasting
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Crushed and suspended TRI with oral intake of enteral nutrition
Number of subjects: 22

Group type: COMPARATOR
Intervention: Whole-tablet TRI with fasting
Number of subjects: 22
Study: 26205311

Group type: EXPERIMENTAL
Intervention: Remote ischemic perconditioning (RIPerc)
Number of subjects: 201
Study: 24921688

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 202
Study: 22722651

Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (15-min infusion)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (30-min infusion)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (60-min infusion)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Oral lacosamide (tablet)
Number of subjects: 51
Study: 20542574

Group type: EXPERIMENTAL
Intervention: Feedback on progress provided to clinicians and patients (n=408)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Monitoring measures without feedback (n=439)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Treatment as usual (n=461)
Number of subjects: 1308
Study: 18988473

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (DM) group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (nondiabetic patients)
Number of subjects: 82
Study: 19901570

Group type: EXPERIMENTAL
Intervention: 90-day Web-based treatment program
Number of subjects: 46
Study: 15014430

Group type: EXPERIMENTAL
Intervention: Linkage analysis at 5p15.3 using six markers
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Linkage analysis restricted to SLE families with 3 or more individuals with alleged RA
Number of subjects: 88
Study: 11136208

Group type: EXPERIMENTAL
Intervention: 2 mg diazepam up to three times daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9249647

Group type: EXPERIMENTAL
Intervention: COX-2 inhibitor (celecoxib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAID (not specified)
Number of subjects: 0
Study: 7943770

Group type: EXPERIMENTAL
Intervention: i.m. DEX (2.5 micrograms/kg) and i.v. placebo (DexPla group)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: i.m. DEX (2.5 micrograms/kg) and i.v. fentanyl (FENT) (1.5 micrograms/kg) (DexFent group)
Number of subjects: 192

Group type: COMPARATOR
Intervention: i.m. MID (0.08 mg/kg) and i.v. FENT (MidFent group)
Number of subjects: 192
Study: 3107849

Group type: EXPERIMENTAL
Intervention: FAM (standard doses of 5-fluorouracil, adriamycin, and mitomycin-C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hi-FAM (high doses of 5-fluorouracil, adriamycin, and mitomycin-C)
Number of subjects: 50